NFE2L2 and amyotrophic lateral sclerosis: Recent studies performedin our laboratory in ALS patient-derived lymphoblasts, which recapitulatefeatures of affected MNs,29 clearly demonstratedthat NRF2 activity appears to be differentially regulated in sALSor SOD1-ALS.30 These dataindicate that pharmacological modulation of NRF2 as a therapeuticstrategy for ALS should be personalized according to the moleculardifferences displayed by the patient.